Press Release: Annual General Meeting of May 3, 2022
03 Mai 2022 - 07:00PM
Press Release: Annual General Meeting of May 3, 2022
Annual General Meeting of May 3, 2022
- Approval of the financial
statements for the fiscal year 2021
- Distribution of a cash dividend of
€3.33 per share and a dividend in kind of EUROAPI shares, at a
ratio of one (1) EUROAPI share per twenty-three (23) Sanofi shares,
with payment as of May 10, 2022
- Board composition: renewals and
appointment of three new Independent Directors
Paris, May
3, 2022. The Combined General
Shareholders’ Meeting of Sanofi was held on May 3, 2022 at
Paris Expo Porte de Versailles, under the chairmanship of Serge
Weinberg. All resolutions submitted to the vote were adopted by the
shareholders.
The General Meeting approved the individual
Company and consolidated financial statements for the fiscal year
2021. The General Meeting decided on the distribution of an
ordinary annual dividend of €3.33 per share and an additional
dividend in kind in the form of an allocation of EUROAPI shares, at
a ratio of one (1) EUROAPI share per twenty-three (23) Sanofi
shares held. The payment of the dividend, including both the cash
dividend and the dividend in kind, will be made on May 10,
2022.
The General Meeting also renewed Paul Hudson,
Christophe Babule, Patrick Kron and Gilles Schnepp as Directors,
and approved the appointment of Carole Ferrand, Emile Voest and
Antoine Yver.
On the proposal of the Nomination, Governance
and CSR Committee, Carole Ferrand has been appointed as member of
the Audit Committee, Barbara Lavernos as member of the Nomination,
Governance and CSR Committee, Wolfgang Laux as member of the
Compensation Committee, and Emile Voest and Antoine Yver as members
of the Scientific Committee.
Following the General Meeting, the Board of
Directors is comprised of 16 members, of whom six are women and two
are Directors representing employees. The Board of Directors
remains for a large majority comprised of Independent
Directors.
The voting results and the videocast of the
Annual General Meeting are available on:
www.sanofi.com/AG2022
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across some 100
countries, is dedicated to transforming the practice of medicine by
working to turn the impossible into the possible. We provide
potentially life-changing treatment options and life-saving vaccine
protection to millions of people globally, while putting
sustainability and social responsibility at the center of our
ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsSandrine
Guendoul | + 33 6 25 09 14 25
| sandrine.guendoul@sanofi.comNicolas
Obrist | + 33 6 77 21 27 55
| nicolas.obrist@sanofi.comVictor
Rouault | + 33 6 70 93 71 40
| victor.rouault@sanofi.com
Investor RelationsEva
Schaefer-Jansen | + 33 7 86 80 56 39
| eva.schaefer-jansen@sanofi.com
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that COVID-19 will have
on us, our customers, suppliers, vendors, and other business
partners, and the financial condition of any one of them, as well
as on our employees and on the global economy as a whole. Any
material effect of COVID-19 on any of the foregoing could also
adversely impact us. This situation is changing rapidly and
additional impacts may arise of which we are not currently aware
and may exacerbate other previously identified risks. The risks and
uncertainties also include the uncertainties discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under “Risk Factors” and “Cautionary
Statement Regarding Forward-Looking Statements” in Sanofi’s annual
report on Form 20-F for the year ended December 31, 2021. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
Sanofi (BIT:1SAN)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Sanofi (BIT:1SAN)
Historical Stock Chart
Von Mär 2023 bis Mär 2024